INTRODUCTION

Proton pump inhibitors (PPIs) are among the most frequently prescribed drugs globally. Although they are cost effective when used appropriately, studies show that they are prescribed without a clear indication in up to 70% of cases. Even though the absolute risk of harm to individuals from PPIs is low, their widespread use can cause adverse effects that contribute to significant negative impacts at a population level. Action is required to limit inappropriate prescribing of PPIs and support deprescribing in patients on long-term therapy for whom the original indications no longer apply. Proton pump inhibitor (PPI) is a prodrug which is activated in the presence of acid. Activated drug (PPI) binds covalently to the gastric H+, K+ -ATPase via disulfide bond. Omeprazole was the first PPI introduced followed by pantoprazole, lansoprazole and rabeprazole. Though these PPIs share the core structures benzimidazole and pyridine, their pharmacokinetics and pharmacodynamics are a little different. Proton pump inhibitors are used mainly to promote healing of gastric and duodenal ulcers and to treat gastroesophageal reflux disease (GERD), including erosive esophagitis, which is either complicated or unresponsive to treatment with H2-receptor antagonists. Proton pump inhibitors are also used as first line treatment for pathological hypersecretory conditions, including the Zollinger-Ellison syndrome.

Available evidences suggest that PPI use is associated with an increased risk of both acute and chronic kidney disease, hypomagnesemia, C difficile infection, and osteoporotic fractures. Caution in prescribing Proton Pump Inhibitors should be used in patients at high risk for any of these conditions. Given the association with kidney disease and low magnesium levels, serum creatinine and magnesium levels should probably be monitored in patients using PPIs, especially those using high doses. All proton pump inhibitors are metabolized by hepatic P450 cytochromes, including CYP2C19 and CYP3A4. Because of short half-lives of proton pump inhibitors, clinically significant drug interactions are rare. The FDA has issued a warning about a potentially important adverse interaction between clopidogrel and proton pump inhibitors.

However, supported by its excellent effectiveness and safety profile, there has been an expansion of its use in inappropriate clinical contexts, such as the prophylaxis of gastrointestinal bleeding in low-risk patients and usage for longer than indicated. This increased prescription of PPI, allied to its growing accessibility due to the

PROSPECTIVE ASSESSMENT OF PRESCRIBING PATTERN OF PROTON PUMP INHIBITORS IN A TERTIARY CARE HOSPITAL IN CHENNAI

Maria K Manu1, Feba John2, Kolli Manikanteswara Rao3, Dr. Samhitha Chetty4, Dr. Adarsh Surendranath4, Dr. Fias Musthafa4

Pharm D Interns1, Assistant Professor2, Gastroenterologist and Endoscopist (MD, DM)3, General Medicine (MD)4

1,2 K. K. College of Pharmacy, The Tamil Nadu Dr. M.G.R. Medical University, Chennai – 600122, India.
3,4 Vijaya Group of Hospital, Vadapalani, Chennai-600026, India.

*Corresponding author’s E-mail: neenukmanu.nkm@gmail.com

Received: 02-11-2020; Revised: 25-12-2020; Accepted: 04-01-2021; Published on: 15-01-2021.

ABSTRACT

The aim of our study was to assess the prescription pattern in patients prescribed with Proton Pump Inhibitors. Our objectives were to analyze the overall use of Proton Pump Inhibitors with regard to Indication, Dose, dosage and Duration of therapy and to assess the changeover of therapy from an oral Proton Pump Inhibitors to IV Proton Pump Inhibitors and vice versa. The Prospective Observational study was conducted in Vijaya hospital, Chennai for 6 months period in patients who were prescribed with PPIs. Demographic details, co-morbidities as well as the prescription details were analyzed. A total of 300 patients were enrolled in the study. PPI were prescribed for drug related conditions in 67% of patients, 9.6% were prescribed for GI disorders. Pantoprazole was the most common choice of PPI. About 23% of the study populations were prescribed with PPI without any indication. The knowledge of prescribing pattern can lead us towards the rational use of drugs and can help us in improving patients quality of life as well as economic burden.

Keywords: PPI, Prescribing pattern, Changeover.
emergence of generics and over-the-counter availability, places PPI amongst the most selling drugs in the world. Drug utilization studies are continuous programs which help us to review, to analyze and to interpret the trends of drug used against pre-determined standards at various levels of the healthcare system. Prescription writing requires regular updating of knowledge and skill, as it reflects the clinical judgments and prescribing pattern. For rational prescription updated knowledge and adherence of prescribing policies is must, while irrational prescription leads to unproductive and risky treatment. Rational use of medicine is defined by the WHO as, ‘Patients receive medications appropriate to their clinical needs, in doses that meet their own individual requirements, for adequate period of time and at lowest cost to them and their community’.

Several guidelines have been published related to appropriate use of PPIs, known as US Food and Drug Administration (USFDA) guideline, American College of Gastroenterological Association (ACG) and the American Gastroenterological Association (AGA) guideline, and National Institute of Clinical Excellence (NICE).

MATERIALS AND METHODS

Study Design

The study is a Prospective Observational study.

Study Site

The study was conducted in a 750 bedded multispeciality hospital located at Vadapalani Chennai.

Study Period and Ethical Clearance

The study was approved (Ref No: 7938/KKCP/2019 dated 04/03/2019) by Institutional Ethics Committee of Vijaya hospital. The study was carried out for the period of 6 months from April 2019 to September 2019.

Study Population Size

A total number of 300 patients based on the sample size were included in the study based on the inclusion and exclusion criteria. The demographic details, clinical data and prescription details were collected from the patients for the study.

Inclusion criteria

- Patients of either sex and aged >18 years
- All In-Patients prescribed with Proton Pump Inhibitors
- Patients who are willing to give consent.

Exclusion criteria

- Patients of either sex and aged 18 or < 18 years
- Patients who are not willing to give consent.
- Patients who are not prescribed with proton pump inhibitors.

Statistical Analysis

The obtained data was entered into Microsoft excel. The demographic descriptive data was reported in terms of mean median and mode.

RESULTS AND DISCUSSION

Our study indicates that the majority of patients within the study population were males (59%) compared to females (41%). In a study conducted by D. G. N Craig et al., reported similar finding in which males were predominant than females. (Fig.1)

In our study the incidence of PPI use was found more in the age group of 51 – 60 years (27%) followed by 61 – 70 years (26%). In a similar study conducted by Jemi Elza et al., most of the patients were observed from the age group between 40 – 60 years, 60 – 80 years and 20 – 40 years. (Fig.2)

The most common co-morbidity among the study population was found to be CVS disorder 26.04% which included 66 hypertensive patients. 14.6% were having endocrine disorders in which majority were having...
Diabetes Mellitus. A similar finding was observed by Mohamed Hassan Elnaem et al.,\textsuperscript{14} in his study.

PPI treatment was given mostly as intravenous preparations, because patients in this study were treated as inpatients. 56.33% patients received PPIs by IV route followed by 43.67% oral route, similar to the study conducted by Saurav Khanal et al.,\textsuperscript{16} where IV route of administration was found to be the most common route of administration (Fig.5).

Our study shows that among the 300 patients, only 23.4% of PPIs prescribed for our patients had no relevant indications. For 9.6% patients PPIs were prescribed for GI disorders and in 67% PPIs were prescribed for drug related indications. This was consistent with the study conducted by Meutia Anindita et al.,\textsuperscript{15} in which the prevalence of PPI usage with appropriate indication was found in 77.78%.(Fig.6)

Use of PPI in patients with abdominal pain or vomiting was considered inappropriate unless the patient had another valid reason for PPI use\textsuperscript{12}. Out of 70 patients, 94.3% of PPIs were prescribed without any indication and 5.7% were prescribed for abdominal pain, nausea and bloody stools

**Changeover Therapy**

The ideal route of administration for any medication is one that achieves serum concentration sufficient to produce the desired effect without producing undesired effects. Patients are switched to oral (PO) therapy to continue treatment after an already adequate course of intravenous therapy being administered. It is not uncommon to convert a patient to oral therapy as part of initial treatment course.

Among the 300 patients, during hospitalization and discharge 48.7% patients had a change-over and 51.3% had no changeover. This result was not in coherence with a prospective study conducted by Shobha Churi et al\textsuperscript{18} (Fig.7)

Among the 139 patients who had a change-over from IV PPI to Oral PPI, 95.65% were from IV Pantoprazole to Oral Pantoprazole followed by 3.55% which were from IV Pantoprazole to Oral Esomeprazole and only 1 patient had a change-over from IV Pantoprazole to Oral Rabeprazole.

Among the 47 patients who had a changeover during hospitalization, 91.6% had a change-over from IV Pantoprazole to Oral Pantoprazole. Among the 103

---

**Figure 3: PPI Used**

In our study, Pantoprazole was the most commonly prescribed PPI among the study population i.e. 97.97% followed by Rabeprazole 2.03%, in accordance to the study conducted by Saurav Khanal et al.,\textsuperscript{16} in which most of the patients were prescribed with Pantoprazole, followed by Rabeprazole. (Fig.3)

**Figure 4: Frequency**

Within the study population, 52% patients received PPI twice daily, followed by 46.33% received PPI once daily in contradiction to the study conducted by Niranjan Kunwar et al \textsuperscript{17}, where PPIs were more prescribed as OD than BD.(Fig.4)

**Figure 5: Route of administration**

Among the 300 patients, during hospitalization and discharge 48.7% patients had a change-over and 51.3% had no changeover. This result was not in coherence with a prospective study conducted by Shobha Churi et al\textsuperscript{18} (Fig.7)

Among the 139 patients who had a change-over from IV PPI to Oral PPI, 95.65% were from IV Pantoprazole to Oral Pantoprazole followed by 3.55% which were from IV Pantoprazole to Oral Esomeprazole and only 1 patient had a change-over from IV Pantoprazole to Oral Rabeprazole.

Among the 47 patients who had a changeover during hospitalization, 91.6% had a change-over from IV Pantoprazole to Oral Pantoprazole. Among the 103
patients who had a change-over during discharge, 90.4% had a change-over from IV Pantoprazole to Oral Pantoprazole followed by 3.9% from IV Pantoprazole to Oral Ranitidine.

CONCLUSION

This large prospective observational study confirms that the majority of PPI prescription within the hospital comprise/consists of Pantoprazole. In our study about 70 patients (23.4%) were prescribed with PPIs without any valid indication which increased the patient therapeutic burden and their treatment cost. Monitoring and evaluating the long-term PPI use in the hospital setting should be performed for attaining a proper outcome and bringing down interaction and other possible issues related to PPI use. The knowledge of prescribing pattern can lead us towards the rational use of drugs and can help us in improving patients quality of life.

REFERENCES

1. Daniel J B Marks. Inappropriate use of proton pump inhibitors can cause a range of side effects and even harm to patients. The pharmaceutical journal, Clinical Pharmacist, 8 AUG 2016.

2. Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J NeurogastroenterolMotil. 2013;19(1):25 35. doi:10.5056/jnm.2013.19.1.25

3. Willemjntje A. Hoogerwerf and Pankaj jay Pasricha. Pharmacotherapy of gastric acidity, peptic ulcer and gastroesophageal reflux disease. In. Laurence L. Brunton(eds.) The Pharmacological Basis of Therapeutics.11, United States of America: McGRAW-HILL;2006, Page-970.

4. Adam Jacob Schoenfeld MD, Deborah Grady MDMPH. Adverse Effects Associated With Proton Pump Inhibitors; JAMA Internal Medicine2016;176(2):172-4. doi: 10.1001/jamainternmed.2015.7927.

5. Kenneth R. McQuaid, MD. Drugs used in the treatment of gastrointestinal diseases. In. Betram G. Katzung (eds.) Basic and Clinical Pharmacology,12. United States of America: The McGraw-Hill ; 2012, Page 1089.

6. Veronica Gamelas, Vera Salvado, Luis Dias. Prescription Pattern of Proton Pump Inhibitors at Hospital Admission and Discharge. Portuguese Journal of Gastroenterology. 2019;26:114-120.

7. Kumar A, Dalai CK, Ghosh A, Kray M. Drug utilization study of co-administration of non-steroidal antiinflammatory drugs and gastroprotective agents in an orthopaedics outpatients department of a tertiary care hospital in West Bangal. Int j basic and clinpharmacol. 2013(March-April);2:199-202.

8. Cheekavolu C, Pathapati RM, Kudagi BL, Saginela SK, makineedi VP, Siddalingappa et al. Evaluation of drug utilization patterns during initial treatment in the emergency room: a retrospective pharmacoepidemiological study. Int scholarly
research network ISRN pharmacology.2011;Article ID 261585:3.

9. WHO policy perspectives on medicines. Promoting rational use of medicine: core components. Geneva: WHO;2002.

10. Ingle P, Patil PH, Lathi V. Study of rational prescribing and dispensing of prescriptions with non-steroidal anti-inflammatory drugs in orthopedic outpatient department. Asian j pharm clin res. 2015;8(4):278-281.

11. National Institute for Clinical Excellence. Management of dyspepsia in adults in primary care. August 2004.

12. Craig DG, Thimappa R, Anand V, Sebastian S. Inappropriate utilization of intravenous proton pump inhibitors in hospital practice—a prospective study of the extent of the problem and predictive factors. QJM. 2010;103(5):327–35.

13. Jemi Elza Varkey, Irene Maria Korah, Nayana Manjally, Shaik Kaleem Basha, Rajeswari R, Krishnamurthy MS. Prescribing Pattern of Proton Pump Inhibitors; Int. J. Pharm. Sci. Rev. Res., July - August 2018; 51(1): 97-102.

14. Mohamed Hassan Elnaem, Mohamad Haniki Nik Mohamed, Amirul Hazim bin Nazar, Rabiatul Nur Khaliasabinti Ibra: Evaluation of Proton Pump Inhibitors Prescribing among Non-Critically Ill Hospitalized Patients in a Malaysian Tertiary Hospital; Journal of Applied Pharmaceutical Science Vol 2017;7(12):077083. DOI: 10.7324/JAPS.2017.71210

15. Meutia Anindita, Nadia Farhan Syafhan, Yetti Hersunaryati, Retnosari Andrajati. Appropriate Use of Proton Pump Inhibitor in Inpatients of Central Army GatotSoebroto Hospital: J Young Pharm 2017; 9(1) Suppl: s9-s12.

16. Saurav Khanal, Kiana Karamifard, Tenzin Choeku, Ms. Safna Mariyam, Dr. Sirinivasa K V. Drug Utilization Evaluation of Proton Pump Inhibitors in General Medicine Department of a Tertiary Care Teaching Hospital. Journal of Biomedical and Pharmaceutical Research, Volume 6, Issue 4; July-August;2017.

17. Nirajan Kunwar, Kumaraswamy M, Surendra Shrestha, Saroj Paudel, Bipin Kafle, Thakur Pokharel, et al. A study on proton pump inhibitors in general medicine unit of tertiary care teaching hospital. World Journal of Pharmaceutical Research. 2015;Vol 4:06.

18. Shobha Churi, Arun Jogani. Prospective Assessment of Prescribing Pattern of Intravenous Proton Pump Inhibitors in an Indian Tertiary-Care Teaching Hospital: Indian Journal of Pharmacy Practice 2014; Vol 7; Issue 4. doi:10.5530/ijopp.7.4.2

Source of Support: None declared.

Conflict of Interest: None declared.

For any question relates to this article, please reach us at: editor@globalresearchonline.net

New manuscripts for publication can be submitted at: submit@globalresearchonline.net and submit_ijpsrr@rediffmail.com